

Rodrigo Liberal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8390014/publications.pdf>

Version: 2024-02-01

57
papers

2,483
citations

236925
25
h-index

197818
49
g-index

58
all docs

58
docs citations

58
times ranked

2937
citing authors

#	ARTICLE	IF	CITATIONS
1	Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis. <i>Hepatology</i> , 2022, 75, 518-530.	7.3	21
2	Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101487.	1.5	5
3	Established and novel therapeutic options for autoimmune hepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 315-326.	8.1	17
4	Discontinuation of antiviral therapy in chronic hepatitis B patients. <i>World Journal of Clinical Cases</i> , 2021, 9, 6979-6986.	0.8	4
5	Transient splenic elastography predicts high-risk esophageal varices in patients with non-cirrhotic portal hypertension. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1462-1466.	1.5	4
6	Acute severe autoimmune hepatitis “timing for steroids and role of other immunosuppressive agents. <i>Journal of Hepatology</i> , 2021, 75, 494-495.	3.7	3
7	Autoimmune hepatitis after COVID-19 vaccine “more than a coincidence. <i>Journal of Autoimmunity</i> , 2021, 125, 102741.	6.5	71
8	Primary biliary cholangitis in patients with inflammatory bowel disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, e5-e9.	1.5	18
9	Letter: liver disease and COVID-19 “not the perfect storm. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 574-575.	3.7	0
10	Cirrhosis management in a major referral center during COVID-19. <i>JHEP Reports</i> , 2020, 2, 100146.	4.9	5
11	Review article: COVID-19 and liver disease “what we know on 1st May 2020. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 267-275.	3.7	137
12	Screening endoscopy in patients with cirrhosis: screening of varices and gastrointestinal neoplasia. <i>Endoscopy</i> , 2020, 52, 623-623.	1.8	0
13	HIPPOCRATES® project: A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting. <i>World Journal of Hepatology</i> , 2020, 12, 1314-1325.	2.0	4
14	Letter: unknown denominator and misleading conclusions in Covid-19 “authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1243-1244.	3.7	0
15	The risk of liver cancer in autoimmune liver diseases. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986191.	3.2	23
16	Another clinical unmet need in liver patients: Multidrug resistant bacteria in decompensated cirrhosis. <i>Journal of Hepatology</i> , 2019, 71, 844-845.	3.7	1
17	Choosing an equation for glomerular filtration rate in decompensated cirrhosis: “Royal Free Hospital” formula is able to predict short-term mortality. <i>International Urology and Nephrology</i> , 2019, 51, 1279-1280.	1.4	1
18	Pediatric-onset primary biliary cholangitis. <i>Digestive and Liver Disease</i> , 2019, 51, 1064-1065.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Predictive models of mortality and hospital readmission of patients with decompensated liver cirrhosis. Digestive and Liver Disease, 2019, 51, 1423-1429.	0.9	23
20	Treatment response in primary biliary cholangitis: The role of autoimmune hepatitis features. Annals of Hepatology, 2019, 18, 488-493.	1.5	1
21	Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?. Liver Transplantation, 2019, 25, 946-959.	2.4	59
22	Endoscopic ultrasound in pancreatic cancer treatment: Facts and hopes. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 513-521.	1.5	6
23	Association Between Black Race and Presentation and Liver-Related Outcomes of Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 1616-1624.e2.	4.4	31
24	Hepatic granulomas: a 17-year single tertiary centre experience. Histopathology, 2018, 73, 240-246.	2.9	7
25	Quality and competence in endoscopic retrograde cholangiopancreatography "Where are we 50 years later?. Digestive and Liver Disease, 2018, 50, 750-756.	0.9	1
26	Looking into Enteric Virome in Patients with IBD. Inflammatory Bowel Diseases, 2017, 23, 1278-1284.	1.9	39
27	Mucosal Healing in Ulcerative Colitis Patients Treated With Vedolizumab: Patient-, Dose-, or Duration-Dependent?. Journal of Crohn's and Colitis, 2017, 11, 1403-1404.	1.3	0
28	Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis. Hepatology, 2017, 66, 1570-1584.	7.3	39
29	Diagnostic performance and factors influencing the accuracy of EUS-FNA for pancreatic adenocarcinoma. Pancreatology, 2017, 17, S81-S82.	1.1	0
30	Liver immunology: How to reconcile tolerance with autoimmunity. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 6-16.	1.5	24
31	Clinical utility of the patency capsule: a large volume center experience. Minerva Gastroenterology, 2017, 64, 10-13.	0.5	3
32	Cirrhosis and autoimmune liver disease: Current understanding. World Journal of Hepatology, 2016, 8, 1157.	2.0	47
33	Recurrence of autoimmune liver disease and inflammatory bowel disease after pediatric liver transplantation. Liver Transplantation, 2016, 22, 1275-1283.	2.4	15
34	CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease. Journal of Autoimmunity, 2016, 72, 102-112.	6.5	40
35	Contemporary issues and future directions in autoimmune hepatitis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1163-1174.	3.0	3
36	Diego and Giorgia Vergani: The two hearts of translational autoimmunity. Journal of Autoimmunity, 2016, 66, 1-6.	6.5	10

#	ARTICLE	IF	CITATIONS
37	Cutting edge issues in autoimmune hepatitis. Journal of Autoimmunity, 2016, 75, 6-19.	6.5	96
38	Update on Autoimmune Hepatitis. Journal of Clinical and Translational Hepatology, 2015, 3, 42-52.	1.4	73
39	“Porto-pulmonary hypertension: A comprehensive review”. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 157-167.	1.5	26
40	In autoimmune hepatitis type 1 or the autoimmune hepatitis “sclerosing cholangitis variant defective regulatory T cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. Hepatology, 2015, 62, 863-875.	7.3	83
41	Regulatory T-cells in autoimmune diseases: Challenges, controversies and “yet” unanswered questions. Autoimmunity Reviews, 2015, 14, 105-116.	5.8	226
42	Octreotide Long-Acting Release is effective in preventing gastrointestinal bleeding due to angiodysplasias. GE Portuguese Journal of Gastroenterology, 2014, 21, 176-183.	0.8	11
43	Diagnostic criteria of autoimmune hepatitis. Autoimmunity Reviews, 2014, 13, 435-440.	5.8	101
44	Dysfunctional CD39 ^{POS} regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology, 2014, 59, 1007-1015.	7.3	158
45	Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2. Journal of Autoimmunity, 2014, 53, 26-32.	6.5	28
46	Management of autoimmune hepatitis: Focus on pharmacologic treatments beyond corticosteroids. World Journal of Hepatology, 2014, 6, 410.	2.0	11
47	Clinical significance of autoantibodies in autoimmune hepatitis. Journal of Autoimmunity, 2013, 46, 17-24.	6.5	85
48	Liver transplantation and autoimmune liver diseases. Liver Transplantation, 2013, 19, 1065-1077.	2.4	83
49	Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 572-585.	1.5	54
50	Autoimmune hepatitis: Contrasts and comparisons in children and adults “ A comprehensive review. Journal of Autoimmunity, 2013, 46, 7-16.	6.5	98
51	Autoimmune hepatitis: A comprehensive review. Journal of Autoimmunity, 2013, 41, 126-139.	6.5	176
52	Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis. Journal of Hepatology, 2013, 59, 1059-1064.	3.7	49
53	Effect of ethnicity on the clinical presentation and outcome of autoimmune hepatitis. Expert Review of Gastroenterology and Hepatology, 2012, 6, 267-269.	3.0	8
54	Autoimmune Hepatitis After Liver Transplantation. Clinical Gastroenterology and Hepatology, 2012, 10, 346-353.	4.4	83

#	ARTICLE	IF	CITATIONS
55	Inhibition of Interleukin-17 Promotes Differentiation of CD25 Cells Into Stable T Regulatory Cells in Patients With Autoimmune Hepatitis. Gastroenterology, 2012, 142, 1526-1535.e6.	1.3	98
56	The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. Hepatology, 2012, 56, 677-686.	7.3	126
57	Pathogenesis of autoimmune hepatitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 653-664.	2.4	131